Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of SI-B001 plus osimertinib in EGFR-mutant advanced or metastatic non-small cell lung cancer after prior EGFR TKI failure
CTR20212943Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Apr 2022; status: active.
02
Drugs
izalontamabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212943.